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Abstract: Cardiovascular disease (CVD) is more common in men and postmenopausal women than premenopausal 
women, suggesting vascular benefits of female sex hormones. Experimental data have shown beneficial vascular effects 
of estrogen including stimulation of endothelium-dependent nitric oxide, prostacyclin and hyperpolarizing factor-mediated 
vascular relaxation. However, the experimental evidence did not translate into vascular benefits of hormone replacement 
therapy (HRT) in postmenopausal women, and HERS, HERS-II and WHI clinical trials demonstrated adverse cardiovas-
cular events with HRT. The lack of vascular benefits of HRT could be related to the hormone used, the vascular estrogen 
receptor (ER), and the subject’s age and preexisting cardiovascular condition. Natural and phytoestrogens in small doses 
may be more beneficial than synthetic estrogen. Specific estrogen receptor modulators (SERMs) could maximize the vas-
cular benefits, with little side effects on breast cancer. Transdermal estrogens avoid the first-pass liver metabolism associ-
ated with the oral route. Postmenopausal decrease and genetic polymorphism in vascular ER and post-receptor signaling 
mechanisms could also modify the effects of HRT. Variants of cytosolic/nuclear ER mediate transcriptional genomic ef-
fects that stimulate endothelial cell growth, but inhibit vascular smooth muscle (VSM) proliferation. Also, plasma mem-
brane ERs trigger not only non-genomic stimulation of endothelium-dependent vascular relaxation, but also inhibition of 
[Ca
2+]i, protein kinase C and Rho kinase-dependent VSM contraction. HRT could also be more effective in the perimeno-
pausal period than in older postmenopausal women, and may prevent the development, while worsening preexisting CVD. 
Lastly, progesterone may modify the vascular effects of estrogen, and modulators of estrogen/testosterone ratio could pro-
vide alternative HRT combinations. Thus, the type, dose, route of administration and the timing/duration of HRT should 
be customized depending on the subject’s age and preexisting cardiovascular condition, and thereby make it possible to 
translate the beneficial vascular effects of sex hormones to the outcome of HRT in postmenopausal CVD. 
Key Words: Estrogen, progesterone, testosterone, hypertension, coronary artery disease, endothelium, nitric oxide, vascular 
smooth muscle, calcium.  
INTRODUCTION 
   The incidence of CVD is greater among men 35-50 years 
of age compared to women of similar age, and in postmeno-
pausal compared to premenopausal women [1,2]. Experi-
mental studies have identified ER in the cytosol and nucleus 
of the endothelium, VSM and adventitial cells of the vascu-
lar wall. Estrogen may activate the cytosolic/nuclear ERs, 
stimulate genomic effects, and induce changes in vascular 
cell growth and vascular tissue remodeling. Estrogen may 
also activate plasma membrane ERs and induce non-genomic 
effects on the endothelium and VSM [1,3,4]. Studies in ani-
mal models of hypertension have shown decreased blood 
pressure in ovariectomized (OVX) female rats treated with 
ER agonists [5]. Also, initial clinical observational studies 
have shown reduced incidence of CVD in postmenopausal 
women receiving HRT [6,7]. However, data from the Heart 
and Estrogen/Progestin Replacement Study (HERS), HERS-
II, and the Women’s Health Initiative (WHI) clinical trials 
did not support beneficial effects of HRT in postmenopausal 
women [8-11] (Table 1). The HERS trial enrolled postmeno-
pausal women with established coronary artery disease and 
failed to demonstrate the benefits of estrogen on secondary 
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cardiovascular prevention. Instead, there was an increase in 
cardiac events within the HRT group in the first year of the 
study [9,10]. The WHI study evaluated the effects of hor-
mones on primary cardiovascular prevention in healthy 
postmenopausal women, and was terminated early due to a 
small but significant increase in cardiovascular events and 
adverse outcomes in the HRT group [11]. The Estrogen Re-
placement in Atherosclerosis (ERA) clinical trial has also 
shown no significant effect of HRT on coronary atheroscle-
rosis as assessed by angiography [12]. These findings have 
directed the avoidance of HRT in postmenopausal women, at 
least in the context of CVD prevention. On the other hand, 
the disappointing outcome of HRT in clinical trials has also 
prompted more careful re-examination of the cardiovascular 
effects of sex hormones.  
  The purpose of this review is to highlight the beneficial 
vascular effects of estrogen observed in experimental stud-
ies, and why translation of these effects into vascular bene-
fits did not materialize in the HRT clinical trials. The lack of 
vascular benefits of HRT in postmenopausal women could 
be related to the hormone used, the vascular hormone recep-
tors, and the subjects studied. In this review, factors related 
to the hormone type, dose, and route of administration will 
be described. Potential postmenopausal changes in vascular 
ER and post-receptor signaling mechanisms of vascular re-
laxation/contraction will also be discussed. Factors related to 
the timing/duration of HRT, the subject’s age and preexisting 310    Current Cardiology Reviews, 2008, Vol. 4, No. 4  Ross et al. 
Table 1.  Summary of Representative HRT Clinical Trials in Postmenopausal Women 
Trial HERS HERS-II WHI  ERA  RUTH KEEPS 
Objective  Whether HRT reduces 
CHD events in women 
with preexisting coro-
nary disease 
Observational 
follow-up to 
HERS 
Whether HRT re-
duces CHD events in 
healthy postmeno-
pausal women 
Whether HRT 
reduces progres-
sion of coronary 
atherosclerosis, 
assessed by angi-
ography 
Whether Raloxifene 
lowers the risk of 
coronary events & 
invasive breast cancer 
Whether HRT 
prevents progres-
sion of carotid 
intimal medial 
thickness and 
accrual of coro-
nary calcium 
Design  Double blind random-
ized clinical trial (DB 
RCT) of secondary 
prevention 
DB RCT of 
secondary pre-
vention 
RCT of primary pre-
vention 
DB RCT  DB RCT  DB RCT of sec-
ondary preven-
tion 
Cohort 
Criteria 
Women with preexist-
ing CAD 
Women with 
preexisting CAD 
Healthy women (no 
history of CAD)  
Women with 
documented CHD;  
half had previous 
MI 
Half had CHD;  re-
mainder had multiple 
CHD risk factors 
Women within 
36 months of 
their final men-
strual period 
Age (yr)  66.7  66.7  63 (50-79)  65.8  55 (mean 68, 39% 
>70) 
42-58 
HRT Used  Oral 0.625 mg CEE + 
2.5 mg MPA/day 
Open-label HRT 
prescribed at 
personal physi-
cians' discretion 
Oral 0.625 mg CEE+ 
2.5 mg MPA/day or 
oral 0.625 mg 
CEE/day 
Oral 0.625 mg 
CEE + 2.5 mg 
MPA/day or oral 
0.625 mg CEE/day 
60 mg/day Raloxifene  0.45 mg/day oral 
CEE;  50 g/day 
weekly transder-
mal estradiol, 
both with cyclic 
oral micronized 
progesterone 
(200 mg/day, 12 
days/mth) 
Number 
Enrolled 
2,763  2,321 consented 
to follow-up 
16,608 with intact 
uterus received 
CEE+MPA;  10,739 
without uterus re-
ceived CEE 
309  10,101 at 187 sites in 
26 countries 
720 
Study 
Duration 
4.1 years (1993 - 1998)  Additional 2.7 
years 
Enrollment began in 
1993;  designed as 15 
year trial 
3.25 years  Enrollment began 
June 1998 
5 years (2005-
2010) 
Outcome  172 MI's and coronary 
deaths in HRT group, 
176 in placebo;  in-
crease in events in first 
year;  beneficial impact 
after 2 years 
No benefit;  
increase in deep 
venous thrombo-
sis (DVT) and 
pulmonary em-
bolism (PE) (RR 
2.89);  total 
events increased;  
261 deaths in 
HRT group, 239 
in placebo 
Stopped CEE/MPA 
arm after 5.2 of 
planned 8.5 yrs;  29% 
increase in MI's, 41% 
increase in stroke, 
doubling of DVT and 
PE, 26% increase in 
breast cancer, de-
crease in colorectal 
cancer and fractures;  
thrombotic risk great-
est in first year;  CEE 
alone found no differ-
ence in MI's, increase 
in stroke, DVT and 
PE's, uncertain effect 
on breast cancer and a 
decrease in fractures 
Angiography de-
tected no differ-
ence in disease 
progression despite 
a favorable effect 
on HDL (increase) 
and LDL (de-
crease) 
Raloxifene reduced 
the risk of invasive 
breast cancer and 
vertebral fractures, 
but did not signifi-
cantly affect the risk 
of CHD, and was 
associated with in-
creased risk of venous 
thromboembolism 
and fatal stroke 
In progress 
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cardiovascular condition will be analyzed. The potential vas-
cular effects of progesterone and testosterone will then be 
discussed. The review will finalize with a perspective on 
potential areas of research that could enhance the vascular 
benefits of HRT in menopausal women. 
TYPES OF HRT 
  The primary source of estrogen in normally cycling adult 
women is the ovarian follicle, which secretes 70 to 500 g 
estradiol daily depending on the phase of the menstrual cy-
cle. In adult women, the plasma levels of estrogen show sig-
nificant fluctuations during the menstrual cycle from 210 
pmol/L in the early follicular and 720 pmol/L in the late fol-
licular phase to 490 pmol/L in the late luteal phase. During 
menopause the ovarian production of estradiol is signifi-
cantly reduced and most endogenous estrogen is produced by 
conversion of androstenedione, secreted by the adrenal cor-
tex, to estrone by peripheral tissues. In postmenopausal 
women, the plasma estrogen level is reduced to <100 
pmol/L, making estrogen the primary and most logical com-
ponent of HRT [13]. 
  The type of estrogen used could affect the outcome of 
HRT in postmenopausal women. Natural estrogens have the 
same structure as the endogenous animal estradiol made by 
the ovaries, and are easily metabolized and excreted. On the 
other hand, semi-synthetic estradiol (estrace) and synthetic 
estrogens are the most widely prescribed. They are similar in 
structure to natural estrogens and have strong vascular ef-
fects, but that comes with unwanted adverse effects [14-16]. 
Examples of synthetic estrogens are diethylstilbestrol, 
ethinyl estradiol (Levlen), and estradiol benzoate (Celerin), 
cypionate and valerate. Mestranol is a prodrug that is quickly 
demethylated in the body to ethinyl estradiol. 
  Conjugated equine estrogen (CEE) is a synthetic estrogen 
and the most commonly prescribed estrogen supplements in 
the United States. CEE is synthesized from the urine of 
pregnant mares and is available in formulas like Premarin, 
Prempro, Premphase and Prempac. CEE has been used in 
most HRT clinical trials, and has been shown to inhibit aortic 
connective tissue remodeling after plasma lipid lowering in 
female monkeys [17]. However, CEE has also been linked to 
increased cancer rates 
  Most of what we learn about estrogen is in reference to 
the two principle estrogens produced in woman’s body, es-
tradiol and estrone, and the horse-derived CEE. Estriol is one 
of the three natural estrogens produced in high levels during 
pregnancy as it is made by the placenta. Although estriol has 
been widely used in Europe for over fifty years, it has not 
received equal attention in the U.S. particularly with regards 
to its vascular effects. Estriol is the weakest of natural estro-
gens and has been used as an alternative to the more potent 
estradiol and estrone for managing menopausal symptoms 
[18]. Because estriol is less potent than estradiol and estrone 
it has little side-effects when used in low doses, and does not 
exhibit strong estrogenic effects such as endometrial and 
breast tissue growth. In a study examining clinically used 
estrogens, estriol, estrone and estrone sulfate did not cause as 
much inhibition of human aortic smooth muscle cell growth, 
proliferation and migration and reduction of mitogen-
activated protein kinase activity as that induced by E2, estra-
diol valerate, estradiol cypionate, or estradiol benzoate [19].  
  “Hormone Bioidenticals” are promoted for managing 
postmenopausal symptoms such as hot flushes and mood 
swings; however, their vascular effects need to be evaluated. 
Bioidentical estriol is available as customized prescriptions. 
Using DNA engineering, sterol analogs found in plants such 
as wild yam are subjected to microbial fermentation and the 
resulting hormone is bioidentical in chemical structure to the 
natural estriol produced in women during pregnancy. 
  Phytoestrogens are chemicals found in plants that bind to 
ER and may act like natural estrogens. Phytoestrogens are 
thousand-fold weaker than estrogen, but circulate in the 
blood at levels thousand-fold higher than natural estrogens 
do [20,21]. Soy isoflavones (genistein, daidzein, equol) are 
major group of phytoestrogens and the most common bo-
tanical supplement used by perimenopausal women. Other 
phytoestrogens include coumestrol, resveratrol, zearalenone, 
-zearalanol, and biochanin A.  
DOSE OF ESTROGEN IN HRT 
  The plasma levels of estrogen decline precipitously dur-
ing menopause. Thus, the primary objective of HRT has of-
ten been to restore the plasma estrogen to levels observed in 
premenopausal women. This view should be analyzed with 
extreme care. Estrogens are highly lipophilic compounds, 
and their circulating levels may not necessarily reflect their 
vascular tissue level. Also, hormones are extensively bound 
to plasma proteins and the hormone pharmacokinetics and 
volume of distribution may change during menopause, par-
ticularly in the presence of kidney, liver or metabolic dis-
ease. Thus, an apparently normal dose of estrogen could lead 
to superphysiological plasma levels in menopausal women, 
and smaller doses of estrogen appear to be as effective as a 
traditional dose [22-24]. 
ROUTE OF ADMINISTRATION OF HRT 
  The outcome of HRT could also vary depending on the 
route of administration. Because estrogens are highly lipo-
philic they are well absorbed when taken orally, and there-
fore various combinations of estrogen have been used in 
clinical trials, mainly as oral pills. However, the first-pass 
metabolism of estrogen in the liver could determine its car-
diovascular effects. Estradiol is rapidly metabolized in the 
liver and is not very effective orally. Ethinyl estradiol is 
more effective orally, and estradiol benzoate is available in a 
slow-release form for parenteral administration. Because of 
their lipophilicity, estrogens are also absorbed through the 
skin. For example, estriol has been used as topical skin 
treatment to manage the effects of aging and menopause by 
decreasing facial wrinkles, smoothing skin, and maintaining 
healthy skin in the vagina and urethra. However, the vascular 
effects associated with the use of topical estriol preparations 
are understudied. Estradiol patches such as Estraderm, Viv-
elle-Dot, Alora, and Climara are also available and trans-
dermal estrogens such as Estrasorb (estradiol topical emul-
sion) may confer more cardiovascular benefits than the oral 
forms. Studies compared markers for atherosclerotic vascular 
disease and endothelial function in healthy postmenopausal 
women receiving oral CEE 0.625 mg/day or transdermal 312    Current Cardiology Reviews, 2008, Vol. 4, No. 4  Ross et al. 
estradiol gel 0.6 mg/day for 6 months. Flow-mediated bra-
chial artery vasodilation was increased in both the oral and 
transdermal HRT groups, suggesting that transdermal estro-
gen, similar to oral estrogen, exerts a positive effect on endo-
thelial function. On the other hand, the levels of the vascular 
inflammatory marker C-reactive protein (CRP) rose in the 
oral but not the transdermal HRT group, suggesting that oral 
estrogen may promote vascular inflammation and atheroscle-
rotic vascular risk, while transdermal estrogen avoids this 
untoward effect and might be more favorable in reducing the 
risk of atherosclerotic vascular disease [25]. Similar results 
were observed in postmenopausal women treated with either 
transdermal estradiol or oral CEE; both routes included 
MPA. CRP levels significantly increased in the women 
orally administered HRT, but did not change in women 
treated transdermally. Also, transdermal estradiol administra-
tion was associated with an increase in the brachial-ankle 
pulse wave velocity, which may be related to the direct effect 
of E2, but no change in the brachial-ankle pulse wave was 
observed in women administered HRT orally. These data 
suggest that transdermal estradiol may reduce the risk of 
atherosclerosis by improving arterial stiffness [26]. 
  Vaginal estrogen in the form of creams, tablets, or rings 
is effective for genitourinary symptoms, and an excellent 
option for nearly all postmenopausal women with the excep-
tion of breast cancer patients. Vaginal estrogen preparations 
can be administered long-term as their systemic absorption is 
low, but their potential long term vascular effects should still 
be considered. 
VASCULAR ESTROGEN RECEPTORS (ERS) 
  Changes in vascular ERs could also occur during meno-
pause, and may influence the outcome of HRT. Vascular 
ERs have been identified in the mouse aorta, rat aorta, ca-
rotid, uterine and tail artery, rabbit uterine artery, bovine 
aorta; primate coronary and carotid artery, and human coro-
nary and uterine artery and umbilical vein. However, a recent 
study has reported that estrogen affects vascular tone and ER 
expression in human arteries, but not in human veins; a find-
ing that should be taken into consideration when examining 
the effects of estrogen on the systemic circulation [27]. ERs 
are expressed in virtually all components of the vascular wall 
including the endothelium, VSM and adventitial cells. Two 
ER subtypes, ER and ER have been identified [3,4,28]. 
However, they are not impervious to genetic polymorphism 
which could affect the receptor binding properties. Truncated 
forms of ER and ER have been described in many tissues, 
including the vascular endothelium [29,30]. Generation of a 
full length mature RNA transcript results in a 66 kDa ER. 
ER variants (55 and 46 kDa) have been described and the 
46 kDa variant is abundant in endothelial cells [29,30]. A 
recent study has demonstrated sex difference in the relation-
ship between arterial stiffness and the -401T/C or 30T/C 
polymorphisms in ER- in older humans. Polymorphisms in 
these genes was associated with decreased brachial-ankle 
pulse-wave velocity in postmenopausal women, but not in 
men [31]. 
  Classical ERs require hours to days to illicit an effect on 
gene expression, while those located in endothelial cells re-
spond to estrogen within minutes [32]. Estrogen diffuses 
through the plasma membrane and forms complexes with 
cytosolic/nuclear ERs, which then bind to chromatin, stimu-
late gene transcription and induce genomic effects. Estrogen 
also binds to signal-generating ERs on the plasma membrane 
of vascular cells and induces rapid non-genomic effects. It 
appears that ER mediates most of the vascular action of 
estrogen, as the same vascular protection is observed in ER 
knockout and wild-type mice [33].  
   Downregulation of vascular ER during menopause could 
take the form of decreased expression of the receptor and/or 
decreased affinity of the receptor to estrogen. Although our 
studies have shown little change in ER expression in the 
aorta of aging compared with adult OVX SHR [34], these 
observations need to be verified in other animal species as 
well as in human vascular tissues. Also, methylation halts the 
activation of gene expression in multiple systems, including 
the cardiovascular system. Methylation of the promoter re-
gion of the ER gene has been associated with the downregu-
lation of the receptor. An age-related increase in ER methy-
lation was observed in vascular tissue. This modification 
could inhibit the protective effects of E2 and could explain 
the diminished benefits of HRT observed in the postmeno-
pausal women [35].  
MODULATORS OF VASCULAR ERS 
  The discovery of different ER subtypes and variants has 
increased the hopes of developing compounds that specifi-
cally target the vascular ER. Tissue-selective ER modulators 
(SERMs) are non-steroidal estrogenic drugs that interact 
with ER, but differ from estrogen in that they elicit either 
agonist or antagonist effects depending on the target
 tissue. 
Examples of SERMs are raloxifene, toremifene, idoxifene 
and tamoxifen [36].  
   SERMs may be more selective in targeting the vascular 
ERs. Tamoxifen positively modulates cerebrovascular tone 
in ovariectomized female rats, acting as an estrogen agonist 
during estrogen deficiency [37]. Similarly, raloxifene elicits 
rapid endothelium-dependent nitric oxide-mediated vasore-
laxation in rat aorta that is not sensitive to either the nonse-
lective ER antagonist ICI 182,780 or the selective ER an-
tagonist 1,3-bis (4-hydroxyphenyl)-4-methyl-5- (4-(2-piperi-
dinylethoxy) phenol)-1H-pyrazole (MPP) [38]. Raloxifene 
also elicits long-term anti-inflammatory actions in rat aortic 
VSM cells via upregulation of ER protein levels [39]. 
  The Raloxifene Use for The Heart (RUTH) clinical trail 
examined the risk-benefit ratio of raloxifene in preventing 
acute coronary events and invasive breast cancer [40]. Al-
though raloxifene reduced the risk of invasive breast cancer 
and vertebral fractures, it did not significantly affect the risk 
of coronary heart disease and was associated with increased 
risk of venous thromboembolism and fatal stroke. Thus the 
benefits of raloxifene in reducing the risks of invasive breast 
cancer and vertebral fracture should be weighed against the 
increased risks of venous thromboembolism and fatal stroke 
[41]. 
  Selective ER agonists and antagonists may be useful in 
maximizing the vascular effects of estrogen while reducing 
its adverse effects on uterine and breast cancer. Diarylpropi-
onitrile DPN is a potent ER
 agonist with a 30- to 70-fold Experimental Vascular Benefits of Sex Hormones  Current Cardiology Reviews, 2008, Vol. 4, No. 4    313 
selectivity over ER [42]. The phytoestrogen biochanin A is 
also a selective ER agonist while RR-tetrahydrochrysene is 
a selective ER antagonist. Ethinyl estradiol is a relatively 
specific ER agonist. Triarylpyrazoles such as propylpyra-
zole trisphenol
 (PPT) are approximately 400-fold more po-
tent on ER than ER [43], and MPP is an ER selective 
antagonist [38].  
POST-RECEPTOR VASCULAR EFFECTS AND SIG-
NALING MECHANISMS 
  Possible changes in the ER post-receptor signaling 
mechanisms could occur during menopause, and may render 
the estrogen-ER interaction in vascular target tissues ineffec-
tive. Studies have shown significant effects of estrogen on 
modification of circulating lipoproteins, inhibition of lipo-
protein oxidation,
 attenuation of atherosclerotic lesions, fa-
vorable modulation of homocysteine, changes in blood co-
agulation, and inhibition of intravascular accumulation of 
collagen. Estrogens may also inhibit the angiotensin convert-
ing enzyme (ACE) and renin release, leading to significant 
changes in the renal hemodynamics and renal control 
mechanisms of the blood pressure [44,45]. In OVX female 
rats, regular subcutaneous administration of E2 appeared to 
prevent an increase in ACE activity, as seen in OVX female 
rats treated with a subcutaneous vehicle [46]. 
  Gender differences in vascular function have also been 
described [1]. Vascular contraction is greater in blood ves-
sels of intact male than intact female rats, not different be-
tween castrated and intact males, but greater in ovariec-
tomized (OVX) than intact females. Estrogen replacement in 
OVX female rats restores the vascular contraction to its level 
in intact females, suggesting that the gender differences in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Cellular mechanisms of estrogen-Induced vascular relaxation and remodeling. In endothelial cells, estrogen binds to cytoso-
lic/nuclear ERs, activates MAPK, and stimulates gene transcription and eNOS expression. Estrogen also binds to surface membrane ERs and 
stimulates Ca
2+ release from the endoplasmic reticulum, the MAPK/Akt pathway, eNOS activity and NO production. NO activates guanylate 
cyclase (GC) and increases cGMP which causes VSM relaxation by inhibiting Ca
2+ influx and stimulating Ca
2+ extrusion. Estrogen’s anti-
oxidant effects cause decreases in NADPH and O2
–• production and increases in NO bioactivity. Estrogen also activates cyclooxygenases 
(COX) and enhances the production of PGI2, which in turn activates adenylate cyclase (AC), increases cAMP, and causes VSM relaxation by 
mechanisms similar to those of cGMP. ER also increases the release of EDHF, activates K
+ channels and causes VSM hyperpolarization and 
inhibition of Ca
2+ influx via Ca
2+ channels. Estrogen also activates cytosolic/nuclear ERs in VSM and inhibits growth factor (GF)-mediated 
activation of MAPK, gene transcription and VSM growth. Estrogen also binds to plasma membrane ERs, decrease [Ca
2+]i and inhibit Ca
2+-
dependent MLC phosphorylation and VSM contraction. Estrogen also inhibits PKC-, MAPK- and Rho kinase and thereby leads to decreases 
in the myofilament force sensitivity to [Ca
2+]i. Dashed arrows indicate inhibition. A: agonist, R: receptor, PLC: phospholipase C, PIP2: 
phospatidyinositol 4,5-bisphosphate, IP3: inositol 1,4,5-trisphosphate, DAG: diacylglycerol, SR: sarcoplasmic reticulum, CAM: calmodulin, 
MLC: myosin light chain, MLCK: MLC kinase, MLCP: MLC phosphatase, MEK: MAPK kinase, CaP: calponin, CaD: caldesmon. 
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vascular contraction may involve direct effects of estrogen 
on the vasculature. 
  Estrogen induces both genomic and non-genomic effects 
in the vasculature. Nuclear ERs act as transcription factors 
that modulate gene expression by directly binding to DNA at 
specific estrogen response elements. ERs could also indi-
rectly prevent transcription of promoters lacking estrogen 
response elements by interacting with nuclear transcription 
factors. ER transcriptional activity may be regulated by in-
tracellular signaling pathways even in the absence of ER 
ligands [36]. Activation of cytosolic/nuclear ERs in endothe-
lial cells triggers genomic effects leading to cell growth and 
proliferation. For example, 17-estradiol (E2) induces the 
phosphorylation and activation of mitogen-activated protein 
kinase (MAPK) and proliferation of endothelial cells (Fig. 1). 
In contrast, E2 inhibits MAPK activity and the growth and 
proliferation of VSM cells [47,48]. E2 could also activate 
plasma membrane ERs in the endothelium and VSM, initiate 
non-genomic effects, and cause reduction in vasoconstriction 
[49].  
ESTROGEN AND THE ENDOTHELIUM 
  E2-induced vasodilation is mediated to a large extent by 
the endothelium [50]. Estrogen induces vascular relaxation 
by modifying the synthesis/release/bioactivity of endothe-
lium-derived relaxing factors such as nitric oxide (NO), 
prostacyclin (PGI2) and hyperpolarizing factor (EDHF), as 
well as contracting factors such as endothelin (ET-1). E2 
potentiates endothelium-dependent flow-mediated vasodila-
tion in postmenopausal women. Also, endothelium-depen-
dent vascular relaxation is greater in female than male spon-
taneously hypertensive rats (SHR). A significant relationship 
exists between the amount of ERs and endothelium-
dependent NO release. Basal release of NO, as determined 
by endothelium-dependent vasodilation is larger in the aorta 
of wild-type male mice than their ER knockout counterparts 
[51]. ER appears to mediate most of the cardioprotective 
actions of estrogen including nongenomic vasodilation 
[52,53]. Estrogen
 treatment increases basal NO production in 
the aorta of mice expressing only functional ER [54]. Also, 
E2-induced vascular relaxation is more pronounced in ER-
deficient mice [55]. Additionally, selective ER agonists 
improve endothelial dysfunction in blood vessels of OVX 
SHR [56]. On the other hand, ER mediates non-genomic 
action in caveolae, where the eNOS enzyme is localized 
[57,58].  
  Total NO production is greater in premenopausal women 
than in men [59]. Similarly, endothelial NO release is greater 
in the blood vessels of female than male rats. Estrogen may 
influence NO production by activating ER-mediated ge-
nomic pathways and up-regulating endothelial NO synthase 
(eNOS). E2 stimulation and ER gene transfer into endothe-
lial cells induces eNOS gene expression. Also, membrane-
impermeant E2 binds to ER at the cell surface, stimulates 
non-genomic increases in [Ca
2+]I, NOS activity and NO re-
lease from human endothelial cells. E2 also promotes the 
association of heat shock protein 90 (Hsp90) with eNOS and 
reduces the Ca
2+ requirement for its activation [60]. The E2-
induced [Ca
2+]i causes transient translocation of eNOS from 
endothelial cell plasma membrane to intracellular sites close 
to the nucleus, while prolonged exposure to E2 induces the 
return of eNOS to the plasma membrane for its full activa-
tion [3]. E2 also induces the phosphorylation/activation of 
eNOS by increasing the activity of MAPK (ERK1/2) or the 
phosphatidylinositol-3 (PI3)-kinase-Akt pathway [61].  
  Estrogen has antioxidant properties that could affect NO 
bioavailability [62]. In OVX female rats, increased blood 
pressure is associated with lower plasma antioxidant levels 
and increased plasma lipoperoxides and vascular free radi-
cals. E2 replacement prevents these effects. Also, the amount 
of superoxide (O2
–•) is greater in blood vessels of male than 
female rats. Furthermore, E2 inhibits NADPH oxidase ex-
pression and the generation of O2
–• and peroxynitrite 
(ONOO
–), thereby enhancing NO bioactivity. 
 PGI2 is produced from the metabolism of arachidonic 
acid by cyclooxygenases (COX). The COX inhibitor indo-
methacin decreases endothelium-dependent vascular relaxa-
tion, and gender differences in indomethacin-sensitive vascu-
lar relaxation have been attributed to differences in COX 
products [63]. Also, E2 causes upregulation of COX-1 ex-
pression and PGI2  synthesis in endothelial cells. Estrogen 
also increases urinary excretion
 of COX-2–derived PGI2 me-
tabolites
 in ER but not ER knock-out mice [64]. 
   Acetylcholine (Ach)-induced hyperpolarization and re-
laxation of mesenteric arteries are reduced in males and 
OVX females as compared to intact female rats, and the dif-
ference is eliminated by K
+ channel blockers. Also, the hy-
perpolarizing response to Ach is improved in E2-replaced 
OVX female rats, confirming that estrogen-deficient states 
attenuate vascular relaxation by endothelium-derived hyper-
polarizing factor (EDHF).  
  E2 modulates ET-1 expression and release in human endo-
thelial cells [65]. Also, prolonged treatment of endothelial 
cells with E2 inhibits ET-1 production in response to serum, 
tumor necrosis factor-, transforming growth factor 1 and 
AngII [66]. Additionally, ET-1 release from endothelial cells 
is less in female than male SHR. ET-1 activates endothelial 
ETB1 receptor and causes the release of relaxing factors that 
promote vascular dilation. ET-1 also stimulates ETA and 
ETB2 receptors and causes VSM contraction. In mesenteric 
arteries of deoxycorticosterone acetate (DOCA)-salt hyper-
tensive rats, contraction to ET-1 is greater in males than fe-
males. Ovariectomy is associated with increased ET-1 and 
ETB receptor mRNA in mesenteric arteries, and E2 replace-
ment reverses these changes. Also, the ETB agonist IRL-
1620 induces less vasoconstriction in intact compared with 
OVX females, and E2 replacement decreases IRL-1620-
induced vasoconstriction in OVX females. These data sug-
gest that ovarian hormones attenuate ET-1/ETB receptor ex-
pression and their vascular responses in DOCA-salt hyper-
tensive rats [67]. 
ESTROGEN AND MECHANISMS OF VSM CON-
TRACTION 
  Estrogen causes relatively rapid relaxation in endothe-
lium-denuded blood vessels [49]. The acute inhibitory ef-
fects of E2 on vascular contraction in vitro are observed at 
ambient concentrations in the micro-molar range, which ex-
ceed the physiological pico-molar concentrations in the Experimental Vascular Benefits of Sex Hormones  Current Cardiology Reviews, 2008, Vol. 4, No. 4    315 
plasma, and are believed to involve non-genomic effects on 
the mechanisms of VSM contraction. The greater plasma 
estrogen levels in females may explain the reduced vascular 
contraction in females compared with males. Also, ERs are 
more abundant in arteries of females compared with those of 
males [68]. E2 also induces downregulation of vascular an-
giotensin AT1 receptor mRNA and protein [46,69]. The gen-
der differences in vascular contraction could also be due to 
differences in the signaling mechanisms of VSM contraction 
downstream from receptor activation. 
  VSM contraction is triggered by increases in [Ca
2+]i due 
to Ca
2+ release from the sarcoplasmic reticulum and Ca
2+ entry 
from the extracellular space. Activation of myosin light chain 
(MLC) kinase, Rho kinase and MAPK also contribute to 
VSM contraction. Also, the agonist-receptor interaction is 
coupled to increased production of diacylglycerol, which acti-
vates protein kinase C (PKC) [70]. 
  In isolated VSM cells incubated in the presence of exter-
nal Ca
2+, phenylephrine (Phe) causes an initial peak in 
[Ca
2+]i mainly due to Ca
2+ release from the intracellular 
stores, and a maintained [Ca
2+]i due to Ca
2+ entry from the 
extracellular space. In Ca
2+-free solution, Phe or caffeine 
causes transient cell contraction and [Ca
2+]i that are not dif-
ferent between intact and gonadectomized male and female 
rats, suggesting that the gender differences in VSM contrac-
tion do not involve Ca
2+ release from the intracellular stores. 
In contrast, the maintained Phe-induced VSM [Ca
2+]i is 
greater in intact male than female rats, suggesting gender 
differences in the Ca
2+ entry mechanism of VSM contrac-
tion. The maintained Phe-induced [Ca
2+]i is greater in OVX 
than intact females, but not different between E2-replaced 
OVX and intact females, or between castrated and intact 
males, suggesting that the gender differences are likely re-
lated to estrogen [71]. The cause of the gender differences in 
Ca
2+ entry may be related to the plasmalemmal density 
and/or permeability of VSM Ca
2+ channels. 
  Estrogen causes rapid relaxation of isolated vessels pos-
sibly through an effect on Ca
2+ mobilization and fluxes. E2 
does not inhibit caffeine- or carbachol-induced VSM con-
traction or [Ca
2+]i in Ca
2+-free solution, suggesting that it 
does not inhibit intracellular Ca
2+ release. On the other hand, 
E2 inhibits maintained agonist- and KCl-induced contrac-
tion, Ca
2+ influx and [Ca
2+]I, suggesting inhibition of Ca
2+ 
entry through Ca
2+ channels [72].
  
 E2  activates  BKCa channels in coronary VSM, leading to 
hyperpolarization and decreased Ca
2+ entry through voltage-
gated channels. In human coronary artery smooth muscle 
cells ER may mediate acute BKCa channel stimulation by 
E2. When the ER mRNA was abolished with an ER 
plasmid, the stimulatory effect of E2 on the BKCa was fully 
eliminated. Because this effect occurred within minutes of 
the introduction of the plamsid, this is thought to be a non-
genomic effect of E2 [73]. However, a direct effect of estro-
gen on Ca
2+ channels has also been suggested. Estrogen may 
also decrease [Ca
2+]i by stimulating Ca
2+ extrusion via plas-
malemmal Ca
2+ pump [74]. 
  The gender differences in vascular contraction could also 
be due to differences in the expression/activity of PKC in 
VSM. Like Phe, phorbol esters, which activate PKC, pro-
duce greater contraction in isolated vessels of intact male 
than female rats, suggesting gender differences in the PKC-
mediated pathway of VSM contraction. PKC is a family of 
several isoforms that have different substrates, functions and 
subcellular distributions. Immunoblot analysis in VSM of 
intact male rats has shown significant amounts of -, - and 
-PKC, and both Phe and phorbol esters cause activation and 
redistribution of - and -PKC. The amount and the Phe- 
and phorbol ester-induced redistribution of - and -PKC are 
less in intact female as compared to male rats, and the gender 
differences in VSM contraction have been related to underly-
ing changes in the amount/activity of -, - and -PKC [75]. 
  The Phe- and phorbol ester-induced VSM contraction and 
PKC activity are not different between castrated and intact 
male rats, but greater in OVX than intact females and E2-
replaced OVX female rats, suggesting an effect of estrogen on 
the expression/activity of PKC. A genomic action of estro-
gen on PKC expression in VSM might well underlie the re-
duction in vascular contraction and PKC activity in female 
rats compared with males. However, additional non-genomic 
effects of sex hormones on the PKC molecule or its lipid co-
factors or other protein kinases upstream from PKC cannot 
be excluded.  
  The small GTPase RhoA has been implicated in focal 
adhesions, and the downstream effector Rho-kinase plays a 
role in the regulation of force and actomyosin crossbridge 
cycling in VSM [76,77]. Rho-kinase may inhibit MLC phos-
phatase leading to increased MLC phosphorylation and en-
hancement of VSM contraction. Rho-kinase may also stimu-
late VSM cell proliferation and migration. Abnormal activa-
tion of the Rho-kinase pathway may play a role in hyperten-
sion and other vascular diseases, and Rho-kinase inhibitors, 
such as fasudil, may be beneficial in CVD [78]. 
  The expression of Rho-kinase is mediated by the 
PKC/NF-B pathway, which is inhibited by estrogen [79]. In 
a study examining gender differences in basilar artery diame-
ter the Rho-kinase inhibitor Y-27632 was 3-fold more potent 
as vasodilator in males than females. Expression of RhoA 
and Rho-kinase did not differ between males and females. In 
OVX rats, vasodilator responses to the Rho kinase inhibitor 
Y-27632 resembled responses in males, and treatment of 
OVX rats with E2 normalized the vasodilator effects of Y-
27632 to those observed in intact females. These data sug-
gest that vascular Rho kinase function is suppressed in fe-
males possibly due to estrogen effects [80]. 
ESTROGEN, THE CYTOSKELETON AND EX-
TRACELLULAR MATRIX (ECM). 
   Estrogen also plays a role in the regulation of the cy-
toskeleton, extracellular matrix and vascular remodeling. 
ER interacts with the G protein G13 to induce activation 
of the RhoA/Rho-kinase pathway and phosphorylation of the 
actin-regulatory protein moesin, leading to remodeling of the 
actin cytoskeleton and endothelial cell migration [81]. Inter-
endothelial junctions are important regulators of endothelial 
cell functions such as migration, proliferation, and angio-
genesis. E2 regulates these functions in vivo and in vitro and 
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monolayer integrity and intercellular adhesion. A recent 
study examined whether E2 affects endothelial cell adhesion-
dependent functions by targeting the adherens junction com-
plex. It was found that E2 increases uterine microvascular 
endothelial cell monolayer permeability and transiently re-
distributes inter-endothelial junction-forming proteins. Con-
comitantly, adherens junction proteins are disconnected from 
the cytoskeleton and -catenin, which links VE-cadherin to 
the cytoskeleton, is redistributed from the membrane and the 
adherens junction complex. Also, E2 increased tyrosine 
phosphorylation of the adherens junction complex, and simi-
lar effects could be provoked by non-cell membrane-per-
meable 17-estradiol-BSA. Additionally, E2 treatment en-
hanced the angiogenic effect of vascular endothelial growth 
factor in an in vitro angiogenesis model, possibly due to the 
adherens junction disruption. Co-treatment with the Src-
family kinase inhibitor PP2 prevented the redistribution and 
phosphorylation of the adherens junction proteins. It was 
concluded that adherens junctions in endothelial cells are a 
downstream target of membrane-associated E2 signaling, 
possibly through Src-family kinases [82]. Mitochondria may 
have physical effects on the cytoskeleton including changes 
in tension, and some of these effects may be mediated by 
estrogen. For example, transmission electron microscopy 
showed an increase in mitochondria size of MCF7 cells 
treated with E2. The E2-induced mitochondrial enlargement 
is associated with stimulation of ROS, which in turn affect 
the elasticity of the actin network [83]. 
  E2 enhances endothelial cell interaction with extracellu-
lar matrix proteins via an increase in integrin expression and 
function [84]. Also, CEE inhibits aortic connective tissue 
remodeling in female monkeys [17]. Matrix metalloprotein-
ases (MMPs) and tissue inhibitors of MMPs play a role in 
the degradation of extracellular matrix proteins and vascular 
remodeling during atherosclerotic progression, and E2 has 
been shown to enhance release of MMP-2 from cultured 
human VSM cells [85]. In a more recent study, MMP levels 
did not increase when transdermal E2 and MPA were admin-
istered to postmenopausal women. However, E2 and MPA 
treatment was associated with decreased carotid intima me-
dia thickness, and reduced levels of circulating vascular in-
flammatory markers, including intercellular adhesion mole-
cule, vascular cell adhesion molecule, E-selectin and mono-
cyte chemoattractant protein [86]. 
ESTROGEN AND VASCULAR INFLAMMATION. 
  Low-grade inflammation has been implicated in CVD, 
and estrogen may affect the course of vascular disease by 
affecting vascular inflammation. In aortic segments of OVX 
mice, estrogen attenuates vascular expression of inflamma-
tion-associated genes and adhesion of monocytes to endothe-
lial cells [87]. Also, E2 via an ER-mediated pathway 
blocks Interferon- induced CD40 and CD40L protein ex-
pression and prevents neutrophil adhesion on porcine aortic 
endothelial cells [88]. ER also appears to mediate anti-
inflammatory effects of estrogen. TNF--induced mRNA 
expression of inflammatory mediators in rat aortic smooth 
muscle cells is attenuated when the cells are treated with E2 
or the ER-selective agonist, diarylpropiolnitrile (DPN) [89]. 
In estrogen-depleted aging OVX rats serum levels of the pro-
inflammatory cytokine TNF- are higher and the sensitivity 
of mesenteric arteries to Phe vasoconstriction is greater 
compared with estrogen-replaced animals. Also, in vivo 
treatment with the TNF- inhibitor etanercept or estrogen 
replacement is associated with reduced Phe constriction of 
mesenteric arteries and decreased vascular expression of 
AngII, angiotensin-converting enzyme and AT1 receptor. 
These data suggest that upregulation of TNF- during estro-
gen deficiency may contribute to enhanced vasoconstriction 
by altering the vascular AngII system [90]. However, the 
effects of estrogen on the inflammatory process may vary 
depending on the estrogen preparation used. For example, in 
healthy postmenopausal women receiving HRT, the levels of 
the vascular inflammatory marker CRP rose in the oral but 
not the transdermal HRT group, suggesting that oral estrogen 
may promote acute inflammation, while transdermal estro-
gen is devoid of these effects [25]. 
ESTROGEN AND VASCULAR FUNCTION AT 
MENOPAUSE 
  Several biological and physiological changes occur at 
menopause, partially due to the significant decrease in 
plasma estrogen levels to < 100 pmol/L. Our data in the ag-
ing OVX SHR model of postmenopausal hypertension have 
shown decreased E2-induced vascular relaxation [34]. Al-
though little change in vascular ER expression was observed 
in aging compared with adult OVX SHR, possible age-
related decreases in the affinity of vascular ER to estrogen or 
reduction in the post-ER signaling mechanisms of endothe-
lium-dependent vasodilation and inhibition of the mecha-
nisms of VSM contraction may occur. One consequence of 
decreased endothelial function associated with aging is en-
hanced reactivity to vasoconstrictors. For example, the role 
of K
+ channels as modulators of endothelium-dependent re-
laxation decreases with age in rats, and the vasodilator re-
sponses become exclusively mediated by NO, while the 
EDHF responses diminish. Also, the expression of prosta-
glandin H synthase 1 and prostacyclin synthase increases 
with age. Additionally, the leakage of O2
–• from mitochon-
dria is believed to increase with age, and the role of mito-
chondria in vascular aging is gaining attention [91]. ERs 
have been found in mitochondria, especially in the cere-
brovascular region and their localization increases the capac-
ity for oxidative phosphorylation, thereby suppressing the 
damage of ROS and increasing the efficiency of energy pro-
duction [92]. These findings are important as they highlight 
the significance of timing of HRT in relation to the onset of 
menopause and subject’s age. 
SUBJECT’S AGE AND TIMING OF HRT 
  The lack of beneficial vascular effects of HRT in post-
menpausal women could be related to the subject age. The 
HERS clinical trial was performed on postmenopausal 
women at advanced age (66.7 years) close in range to aver-
age age of enrollment in the WHI which was 62.5 years, or 
12 years post-menopause. The Estrogen Replacement and 
Atherosclerosis (ERA) trial evaluated the flow-mediated 
vasodilation of the brachial artery in postmenopausal women 
(mean age 65.8 years) with established coronary atheroscle-
rosis being treated with combined E2 and MPA HRT, unop-
posed E2, and a placebo. No significant statistical difference 
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the three groups. The absence of an effect on brachial endo-
thelial function in women of this advanced age may explain 
the lack of benefit of E2 in secondary prevention of coronary 
heart disease [93]. Because the vascular expression or re-
sponsiveness of ERs may decline with advanced age HRT is 
expected to be more beneficial if started early in menopause 
rather than in older postmenopausal women. This is sup-
ported by a macaque atherosclerosis study in which OVX 
monkeys were placed on a high cholesterol diet in the ab-
sence or presence of HRT. Those placed on HRT at the time 
of surgical menopause had a 70% reduction in coronary athe-
rosclerosis. In contrast, when HRT was delayed 2 years, the 
beneficial effect was lost [94]. Another study has shown that 
the administration of E2 in postmenopausal women, ranging 
from 45-72 years of age, only mediated improvements in 
flow-mediated vasodilation in the younger sub-population, 
under age 50. However, in all subjects, plasma concentra-
tions of nitrite/nitrate were increased 7.5-fold [95]. In further 
support of the notion that age affects the results of HRT, 
significant decreases in flow-mediated dilation in postmeno-
pausal women receiving short-term transdermal E2 were 
observed in those less than 60 years of age, but for those 
greater than age 60, no alterations in their flow-mediated 
dilation response were observed [96]. Interestingly, further 
sub-group analysis of data from the WHI study showed 
beneficial cardiovascular effect of HRT in women 50 to 59 
years of age, although the data are under-powered to achieve 
statistical significance, based on the sub-group size [97,98]. 
Recent clinical trials appear to address some of these con-
cerns. The Kronos Early Estrogen Prevention Study 
(KEEPS), which began in mid-2005, is a randomized con-
trolled multicenter 5-year clinical trial that will evaluate the 
effectiveness of low dose CEE, and weekly transdermal es-
tradiol (both in combination with cyclic oral, micronized 
progesterone) in preventing progression of carotid intimal 
medial thickness and the accrual of coronary calcium in early 
menopausal women (aged 42-58 years) who are within 36 
months of their final menstrual period, and will examine 
surrogate end points as well as risk factors for atherosclerosis 
[99]. 
HRT AND PREEXISTING CARDIOVASCULAR 
CONDITION 
  HRT could be more effective in reducing the incidence or 
the development of CVD rather than treatment of preexisting 
CVD. In effect, the HERS clinical trial enrolled women with 
pre-established CVD. Also, the subjects enlisted in the ERA 
and RUTH clinical trials were at high risk of coronary heart 
disease. The Women's Angiographic Vitamin and Estrogen 
(WAVE) clinical trial demonstrated that postmenopausal 
subjects with coronary disease did not experience any im-
provement in cardiovascular function as measured by flow-
mediated vasodilation, when administered HRT or antioxi-
dant vitamins for approximately three years [100]. The num-
ber of ER in atherosclerotic plaques is significantly reduced 
compared to those found in normal segments of human coro-
nary arteries [51]. As described above, beneficial effects of 
estrogen in atherogenesis include a decrease in LDL oxida-
tion and binding as well as a decrease in smooth muscle cell 
proliferation. Also, estrogen decreases cell adhesion mole-
cules, macrophage accumulation and monocyte adhesion. 
Additional beneficial estrogen effects include an increase in 
endothelial function and vasodilation. Thus HRT given early 
during perimenopause may decrease the development/ pro-
gression of fibrous cap and atherogenic plaque and reduce 
lesion development. Adversely, in already established athero-
genic plaques estrogen may increase inflammation, MMP 
expression and neovascularization leading to increased le-
sion progression, plaque instability and rupture/hemorrhage, 
respectively. This may explain the reduced vascular benefits 
of HRT in postmenopausal women with preexisting CVD 
and further underscore the importance of HRT timing. 
ROLE OF PROGESTERONE 
  The hormone combination used could also affect the out-
come of HRT in postmenopausal CVD, and progesterone 
may alter the vascular effects of estrogen. Plasma progester-
one ranges from 1.5 nmol/L in the follicular phase to 35 
nmol/L in the mid-luteal phase, and significantly decreases 
to < 1 nmol/L during menopause. Also, progesterone recep-
tors have been identified in the endothelium and VSM of 
vascular beds of the mouse, rat, rabbit, primates as well as 
human. In addition to natural progesterone several synthetic 
progestins are available including medroxyprogesterone ace-
tate (MPA), norethisterone, norgestimate, 3-keto-desogestrel, 
levonorgestrel and gestodene. Also, a highly publicized pro-
gesterone antagonist is RU486 (Mifepristone). 
  Similar to E2, progesterone has anti-atherosclerotic ef-
fects, decreases LDL and increases HDL. Also, progesterone 
stimulates eNOS expression, NO production and NO-
mediated relaxation in rat aorta, porcine coronary artery and 
ovine uterine artery. It has been shown that subcutaneous 
administration of natural progesterone, not MPA, restores the 
endothelium-dependent attenuation of contractile responses 
to phenylephrine in the mesenteric arteries OVX rats [101]; 
therefore the use of synthetic progesterone in research stud-
ies should be further evaluated. Progesterone may also cause 
direct nongenomic COX activation and increase vascular 
PGI2 production. Progesterone inhibits VSM prolifera-
tion/migration and facilitates the inhibitory effects of estro-
gen. Progestins may also modify the effects of E2 on vascu-
lar contraction or cause rapid relaxation in endothelium-
denuded blood vessels [49]. The effects of progesterone on 
VSM [Ca
2+]i are not clear, but acute application of proges-
terone decreases Ca
2+ influx and [Ca
2+]i in rabbit and porcine 
coronary VSM [72]. Also, progesterone inhibits phorbol ester-
induced contraction, PKC activation and translocation in VSM, 
an effect possibly mediated by increasing cAMP levels in VSM 
[102]. 
  We should note that the combined endothelium-depen-
dent and endothelium-independent vasorelaxant effects of 
progesterone are less than those of estrogen. Also, progester-
one may affect vascular relaxation in a tissue-specific fash-
ion. For example, progesterone counteracts the stimulatory 
effects of estrogen on NO production and vascular relaxation 
in canine coronary artery. Also, progesterone antagonizes the 
vasoprotective effect of estrogen on antioxidant enzyme ex-
pression and function and enhances NADPH oxidase activity 
and the production of reactive oxygen species in OVX mice 
[103]. Additionally, progesterone causes upregulation of vas-
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that could enhance vasoconstriction [46,69]. Although the 
anti-inflammatory effects of estrogen would attenuate 
ischemic brain injury, this vasoprotective benefit may be 
diminished in the presence of progestins [104]. Similarly, the 
addition of progesterone to E2 treatment was shown to abol-
ish the benefits of E2 alone on increases in HDL-cholesterol 
in postmenopausal women with hypercholesterolemia and 
hypertension [105]. Also, in OVX female rats LPS induces 
cerebrovascular iNOS and COX-2, and this effect is de-
creased in E2 replaced rats. In contrast, treatment of OVX 
females with either MPA or progesterone exacerbated the 
cerebrovascular inflammatory response to LPS. Additionally, 
CEE alone, but not in combination with MPA, inhibit aortic 
connective tissue remodeling after plasma lipid lowering in 
female monkeys [17]. Furthermore, MPA appears to antago-
nize the inhibitory effects of CEE on coronary artery athero-
sclerosis [106]. 
ROLE OF ANDROGENS 
  Endogenous testosterone levels may also affect the out-
come of HRT in postmenopausal women. Total plasma tes-
tosterone in adult females range between 1.0 to 1.5 nmol/L. 
Although plasma testosterone may decline during meno-
pause to 0.3-0.5 nmol/L, the androgen/estrogen ratio is in-
creased in postmenopausal women. Androgen receptors have 
been identified in the mouse, rat, rabbit and bovine aorta as 
well as in primate coronary artery and human internal mam-
mary artery [107]. In addition to natural testosterone and 
dihydrotestosterone, there exist testosterone precursors and 
synthetic androgens, including androstenedione, dehydroepi-
androsterone and cyproterone acetate. Androgen receptor 
antagonists such as flutamide, hydroxyflutamide, and bicalu-
tamide are also available. 
  Testosterone is anti-atherosclerotic and may exert benefi-
cial effects on the development of coronary atherosclerosis. 
It is likely that some of the effects of testosterone are due to 
its conversion into estradiol by aromatase and activation of 
ER. However, a direct role of androgens on the vascular wall 
has been proposed. Testosterone induces direct vasodilation 
in some vascular preparations [49]. The non-genomic vascu-
lar effects of testosterone involve both endothelium-depen-
dent mechanisms and direct effects on VSM [107]. In a re-
cent study, testosterone was found to be positively correlated 
to flow-mediated dilation in the brachial artery of postmeno-
pausal women; where women with greater concentrations of 
testosterone had greater dilation compared to those with de-
creased concentrations [108]. When testosterone is acutely 
administered in canine coronary vessels it induces NO-
mediated vasodilation. Also, dehydroepiandrosterone stimu-
lates NO production in human endothelial cells by enhancing 
the expression/stabilization of eNOS. In SHR blood vessels, 
testosterone appears to release EDHF and causes VSM hy-
perpolarization by a mechanism involving large conductance 
Ca
2+-dependent K
+ channels (BKCa) [109]. Testosterone also 
modulates VSM cell proliferation in a dose-dependent man-
ner, with low concentrations stimulating and high concentra-
tions inhibiting DNA synthesis and VSM growth [1]. A por-
tion of testosterone-induced vasorelaxation is endothelium-
independent and may involve ATP-sensitive K
+ channels 
(KATP) in VSM [110]. Studies suggest that testosterone in-
duces vasorelaxation by inhibiting Ca
2+ influx and decreas-
ing [Ca
2+]i in VSM [72]. The vasorelaxant effect of testos-
terone is attenuated by K
+ channel blockers, suggesting that 
stimulation of K
+ conductance is involved in the inhibitory 
effects of testosterone on VSM [Ca
2+]I. Also, dihydrotestos-
terone decreases TNF- and LPS-induced inflammatory re-
sponse in human endothelial cells [111]. 
  Some studies suggest the use of androgen supplements to 
enhance libido and social well-being in menopausal women. 
However, androgens may have adverse effects on the rennin-
angiotensin system and the kidney and could play a role in 
the development of some forms of hypertension [2,112]. 
Specific androgen antagonists may block the harmful effect 
of androgens on the kidney while enhancing their beneficial 
vascular effects. 
PERSPECTIVE 
  The greater incidence of CVD in men and postmeno-
pausal women compared with premenopausal women is re-
lated to effects of sex hormones on vascular function. Al-
though experimental studies suggest both genomic and non-
genomic beneficial effects of estrogen on the endothelium, 
VSM and adventitial cells, these effects did not translate into 
vascular benefits in clinical trials of HRT in postmenopausal 
women. The lack of vascular benefits of HRT in postmeno-
pausal women appears to involve several factors related to 
the hormone used, the vascular ERs and the subjects’ age 
and preexisting cardiovascular condition.  
  New directions of HRT research should focus on com-
pounds that specifically target the vascular ERs. For exam-
ple, selective ER agonists improve endothelial dysfunction 
in estrogen-deficient rats [56]. Also, SERMs could be more 
specific in targeting the vascular ERs with little undesirable 
growth promoting effects on breast cancer. Natural hor-
mones that avoid first-pass metabolism in the liver could be 
more effective HRT. Likewise, transdermal estrogen may be 
more beneficial than oral estrogen in enhancing vascular 
relaxation, while reducing vascular inflammation. Estradiol 
metabolism may also determine its cardiovascular effects, 
and nonfeminizing estradiol metabolites may confer cardio-
vascular protection in both genders. Furthermore, phytoes-
trogens and “hormone bioidenticals” may provide a more 
natural dietary source of estrogen replacement than synthe-
sized compounds. 
  The ER subtypes, distribution and function in vascular 
cells also need to be further examined. ER variants and trun-
cated forms of ER and ER have been identified in many 
tissues including the endothelium and VSM and may alter 
the vascular effects of estrogen [29,30]. Also, the subcellular 
distribution of ERs at the cell membrane, cytosol and nuclear 
compartment could determine the net genomic and nonge-
nomic vascular effects of estrogen. Additionally, ERs are 
phosphoproteins, and mutations in phosphorylation sites may 
affect their transactivation capacity. Differences in ER sub-
types, subcellular distribution and post-receptor signaling 
mechanisms may explain why estrogen enhances endothelial 
cell growth, but inhibits VSM proliferation. For example, in 
mice with genetic ER deletion, the cardioprotective role
 of 
estrogen in ischemia/reperfusion injury is lost [113,114]. On 
the other hand, genetic deletion of ER results
 in the devel-
opment of hypertension [28]. Experimental Vascular Benefits of Sex Hormones  Current Cardiology Reviews, 2008, Vol. 4, No. 4    319 
  In addition to nuclear ERs that mediate the classic ge-
nomic effects of estrogen, estrogen binds to cell membrane 
ERs and induces rapid nongenomic effects on the mecha-
nisms of vascular relaxation/contraction. These effects in-
clude increased endothelium-derived vasodilators as well as 
inhibition of VSM [Ca
2+]I, PKC and Rho kinase. Other signal-
ing pathways such as MLC kinase and phosphatase, and ty-
rosine kinase could regulate VSM contraction, and the 
changes in the expression/activity of these protein kinases 
and phosphatases with gender and gonadal hormones need to 
be further examined. 
  The lack of vascular benefits of HRT in postmenopausal 
women could also be related to its timing/duration and the 
subjects’ age or preexisting cardiovascular condition. Studies 
have shown that ovariectomy augments hypertension in ag-
ing female Dahl salt-sensitive rats [115]. Also, age-related 
reduction in ER-mediated mechanisms of vascular relaxation 
has been observed in blood vessels of female SHR, provid-
ing evidence that the vascular effects of estrogen change 
with aging [34]. Studies such as the KEEPS clinical trial are 
needed to clarify whether using HRT in women within the 
menopausal transition can provide cardiovascular protection. 
Also, the type, dose, timing/duration of estrogen treatment 
should be customized depending on the subject’s age and 
preexisting cardiovascular condition. 
  Similar to estrogen, progesterone appears to confer car-
diovascular effects and could modify the vascular effects of 
estrogen, and therefore, the benefits/risks of including pro-
gesterone in the HRT combination should be further exam-
ined. Although androgens may be involved in some forms of 
hypertension by up-regulating the renal renin-angiotensin 
system, data suggest an effect of testosterone on the vascular 
control mechanisms of blood pressure. The effects of testos-
terone on the mechanisms of vascular relaxation/contraction 
warrant further examination of its role in coronary artery 
disease and hypertension. However, it is important to note 
that sex steroids have different sexual effects, and their vas-
cular effects may be different in males and females. Gender 
differences in the inhibitory effects of estrogen on vascular 
contraction have also been observed [116]. Although modu-
lators of the effects of progesterone and testosterone may be 
beneficial in postmenopausal women, steroid hormones have 
the same pregnenolone origin, and blocking one pathway 
may shift the hormonal balance. Thus, the relative vascular 
benefits of sex hormones should always be weighed against 
potential vascular risks of HRT in postmenopausal women. 
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cAMP  =  Cyclic adenosine monophosphate 
COX =  Cyclooxygenase 
DOCA =  Deoxycorticosetrone  acetate 
E2 =  17-estradiol 
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